ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

BHVN Biohaven Ltd

40,69
0,79 (1,98%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Biohaven Ltd BHVN NYSE Common Stock
  Änderung Änderung % Aktuell Zeit
0,79 1,98% 40,69 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
40,72 40,45 42,105 40,69 39,90
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
22.4.202422:05PRNUSBiohaven Announces Closing of Public Offering and Full..
17.4.202422:05PRNUSBiohaven Announces Proposed Public Offering of Common Shares
13.4.202415:00PRNUSBiohaven Showcases Innovative Neuroscience Portfolio with 20..
29.2.202422:16EDGAR2Form 8-K - Current report
29.2.202422:05PRNUSBiohaven Reports Fourth Quarter and Full Year 2023 Financial..
08.1.202413:30EDGAR2Form 8-K - Current report
08.1.202413:30PRNUSBiohaven Highlights Progress Across Innovative Portfolio and..
02.1.202413:00PRNUSBiohaven to Present at the 42nd Annual J.P. Morgan..
01.12.202322:30PRNUSBiohaven Presents Expanded EEG and Safety Data for BHV-7000..
14.11.202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14.11.202322:05PRNUSBiohaven Reports Third Quarter 2023 Financial Results and..
16.10.202313:00PRNUSBiohaven Presents Preclinical Data Demonstrating..
05.10.202322:05EDGAR2Form 8-K - Current report
05.10.202322:05PRNUSBiohaven Announces Closing of Public Offering and Full..
04.10.202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03.10.202305:56PRNUSBiohaven Announces Pricing of $225 Million Public Offering..
03.10.202303:41EDGAR2Form 8-K - Current report
02.10.202323:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02.10.202323:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02.10.202322:36PRNUSBIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
02.10.202322:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
27.9.202312:58EDGAR2Form 8-K - Current report
14.9.202313:00PRNUSBiohaven Completes Enrollment in Pivotal Phase 3 Study of..
05.9.202313:00PRNUSBiohaven Announces Positive Data from its Exploratory..
31.7.202323:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31.7.202322:29EDGAR2Form 8-K - Current report
31.7.202315:31PRNUSBiohaven's Taldefgrobep Alfa Receives EU Orphan Drug..
31.7.202312:59PRNUSBiohaven Reports Second Quarter 2023 Financial Results and..
28.7.202322:35EDGAR2Form 8-K - Current report
27.7.202314:42DJNBiohaven Told That FDA Won't Review NDA Application for..
27.7.202313:00PRNUSBiohaven Provides Preliminary EEG Data Update for Kv7..
31.5.202313:00PRNUSBiohaven Provides Overview of Clinical Progress, Regulatory..
25.5.202323:00PRNUSBiohaven to Present R&D Day at Yale School of Management
12.5.202322:30PRNUSBiohaven Reports First Quarter 2023 Financial Results and..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock